Skip to main content
. Author manuscript; available in PMC: 2023 Feb 10.
Published in final edited form as: Sci Transl Med. 2022 Aug 10;14(657):eabj2109. doi: 10.1126/scitranslmed.abj2109

Fig. 1 |. Association of ESKD risk in Discovery cohort with baseline concentration of 25 circulating candidate proteins. Results of univariate Cox regression analysis.

Fig. 1 |

Effect size (Hazard Ratio and 95% CI) in Discovery cohort is presented per standard deviation change in protein concentration. Proteins are grouped to TGF-β signaling, BMP signaling, and Activin signaling. Bonferroni correction for n=25 independent tests (the number of examined proteins by the study design) yielded a threshold of P < 2.0×10−3. Bonferroni correction for n=1,129 independent tests (the number of proteins on SOMAscan) yielded a threshold of P < 4.0×10−5. Red dots show proteins that were replicated and validated in other study cohorts. See Supplementary Table S2

* Proteins which were measured only in 113 out of 219 subjects in the Discovery cohort in the 1st stage of SOMAscan screening (see methods).

Anti-Muellerian hormone type-2 receptor (AMHR2) was significant (Bonferroni corrected P=0.024) in the 1st stage, but was not measured in the 2nd stage due to technical reasons.